Cargando…

Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics

Prostate cancer (PCa) is the most frequently diagnosed cancer worldwide and the second most common cause of cancer-related deaths among men. Progress in molecular imaging has magnified its clinical management; however, an unmet clinical need involves the identification of new imaging biomarkers that...

Descripción completa

Detalles Bibliográficos
Autores principales: Laudicella, Riccardo, Spataro, Alessandro, Crocè, Ludovica, Giacoppo, Giulia, Romano, Davide, Davì, Valerio, Lopes, Maria, Librando, Maria, Nicocia, Antonio, Rappazzo, Andrea, Celesti, Greta, Torre, Flavia La, Pagano, Benedetta, Garraffa, Giuseppe, Bauckneht, Matteo, Burger, Irene A, Minutoli, Fabio, Baldari, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047910/
https://www.ncbi.nlm.nih.gov/pubmed/36980482
http://dx.doi.org/10.3390/diagnostics13061175
_version_ 1785014045346103296
author Laudicella, Riccardo
Spataro, Alessandro
Crocè, Ludovica
Giacoppo, Giulia
Romano, Davide
Davì, Valerio
Lopes, Maria
Librando, Maria
Nicocia, Antonio
Rappazzo, Andrea
Celesti, Greta
Torre, Flavia La
Pagano, Benedetta
Garraffa, Giuseppe
Bauckneht, Matteo
Burger, Irene A
Minutoli, Fabio
Baldari, Sergio
author_facet Laudicella, Riccardo
Spataro, Alessandro
Crocè, Ludovica
Giacoppo, Giulia
Romano, Davide
Davì, Valerio
Lopes, Maria
Librando, Maria
Nicocia, Antonio
Rappazzo, Andrea
Celesti, Greta
Torre, Flavia La
Pagano, Benedetta
Garraffa, Giuseppe
Bauckneht, Matteo
Burger, Irene A
Minutoli, Fabio
Baldari, Sergio
author_sort Laudicella, Riccardo
collection PubMed
description Prostate cancer (PCa) is the most frequently diagnosed cancer worldwide and the second most common cause of cancer-related deaths among men. Progress in molecular imaging has magnified its clinical management; however, an unmet clinical need involves the identification of new imaging biomarkers that complement the gold standard of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in cases of clinically significant PCa that do not express PSMA. Fibroblast activation protein (FAP) is a type II transmembrane serine overexpressed in many solid cancers that can be imaged through quinoline-based PET tracers derived from an FAP inhibitor (FAPi). Preliminary results of FAPi application in PCa (in PSMA-negative lesions, and in comparison with fluorodeoxyglucose—FDG) are now available in the literature. FAP-targeting ligands for PCa are not limited to detection, but could also include therapeutic applications. In this preliminary review, we provide an overview of the clinical applications of FAPi ligands in PCa, summarising the main results and highlighting contemporary strengths and limitations.
format Online
Article
Text
id pubmed-10047910
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100479102023-03-29 Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics Laudicella, Riccardo Spataro, Alessandro Crocè, Ludovica Giacoppo, Giulia Romano, Davide Davì, Valerio Lopes, Maria Librando, Maria Nicocia, Antonio Rappazzo, Andrea Celesti, Greta Torre, Flavia La Pagano, Benedetta Garraffa, Giuseppe Bauckneht, Matteo Burger, Irene A Minutoli, Fabio Baldari, Sergio Diagnostics (Basel) Review Prostate cancer (PCa) is the most frequently diagnosed cancer worldwide and the second most common cause of cancer-related deaths among men. Progress in molecular imaging has magnified its clinical management; however, an unmet clinical need involves the identification of new imaging biomarkers that complement the gold standard of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in cases of clinically significant PCa that do not express PSMA. Fibroblast activation protein (FAP) is a type II transmembrane serine overexpressed in many solid cancers that can be imaged through quinoline-based PET tracers derived from an FAP inhibitor (FAPi). Preliminary results of FAPi application in PCa (in PSMA-negative lesions, and in comparison with fluorodeoxyglucose—FDG) are now available in the literature. FAP-targeting ligands for PCa are not limited to detection, but could also include therapeutic applications. In this preliminary review, we provide an overview of the clinical applications of FAPi ligands in PCa, summarising the main results and highlighting contemporary strengths and limitations. MDPI 2023-03-19 /pmc/articles/PMC10047910/ /pubmed/36980482 http://dx.doi.org/10.3390/diagnostics13061175 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Laudicella, Riccardo
Spataro, Alessandro
Crocè, Ludovica
Giacoppo, Giulia
Romano, Davide
Davì, Valerio
Lopes, Maria
Librando, Maria
Nicocia, Antonio
Rappazzo, Andrea
Celesti, Greta
Torre, Flavia La
Pagano, Benedetta
Garraffa, Giuseppe
Bauckneht, Matteo
Burger, Irene A
Minutoli, Fabio
Baldari, Sergio
Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics
title Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics
title_full Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics
title_fullStr Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics
title_full_unstemmed Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics
title_short Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics
title_sort preliminary findings of the role of fapi in prostate cancer theranostics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047910/
https://www.ncbi.nlm.nih.gov/pubmed/36980482
http://dx.doi.org/10.3390/diagnostics13061175
work_keys_str_mv AT laudicellariccardo preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT spataroalessandro preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT croceludovica preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT giacoppogiulia preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT romanodavide preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT davivalerio preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT lopesmaria preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT librandomaria preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT nicociaantonio preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT rappazzoandrea preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT celestigreta preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT torreflaviala preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT paganobenedetta preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT garraffagiuseppe preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT baucknehtmatteo preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT burgerirenea preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT minutolifabio preliminaryfindingsoftheroleoffapiinprostatecancertheranostics
AT baldarisergio preliminaryfindingsoftheroleoffapiinprostatecancertheranostics